According to the announcement of Zhaoyan New Pharmaceutical, the daily closing price increase deviation value of the company's stock exceeded 20% during the 3 consecutive trading days of July 14, July 15, and July 16, 2026, which was an abnormal fluctuation. After self-inspection, the company currently produces and operates normally, and there is no important information that should have been disclosed but not disclosed. The company expects net profit from January to June 2026 to 600 million yuan, an increase of 884.9%-1377.4%; after deducting non-net profit of 561 million yuan to 842 million yuan, an increase of 2334.2% to 3551.3% over the previous year. The company suggests that the stock price will rise significantly in the short term, and there is a risk of speculation and fluctuations in the value of biological assets.

According to the announcement of Zhaoyan New Pharmaceutical, the daily closing price increase deviation value of the company's stock exceeded 20% during the 3 consecutive trading days of July 14, July 15, and July 16, 2026, which was an abnormal fluctuation. After self-inspection, the company currently produces and operates normally, and there is no important information that should have been disclosed but not disclosed. The company expects net profit from January to June 2026 to 600 million yuan, an increase of 884.9%-1377.4%; after deducting non-net profit of 561 million yuan to 842 million yuan, an increase of 2334.2% to 3551.3% over the previous year. The company suggests that the stock price will rise significantly in the short term, and there is a risk of speculation and fluctuations in the value of biological assets.